Updated on 31 July 2014
In response to the allegations, the firm's executive vice president Mr Gregg Alton argued that the drug is priced differently around the world. In Egypt, which has a high rate of hepatitis C, the drug will cost just $300 per month, he added.
Mr Alton noted that the firm aimed to provide generic licensing for the drug which would push down the prices further.
A new study conducted by researchers at the University of Liverpool revealing that the Solvadi pill can be made for a few US cents, and that even at $1 a pill, Gilead is set to make good money.
Mr Kaplan said, "Gilead is raking profits with its second-quarter sales of Sovaldi summing up to a whopping $3.5 billion. We are not at all against Gilead making money and we all recognize and agree that originator companies make investments, and that they should be appropriately rewarded. However, what that appropriate reward is and the lack of transparency in how pharmaceutical originators,come up with that price is not in touch with reality."